AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34376536
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (irAE without early high-dose GCC use)
Trial: 32058596
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of octanoic acid‐rich MCT (OAR)
Trial: 32058596
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of decanoic acid‐rich MCT (DAR)
Trial: 32058596
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of MCT (OAR or DAR)
Trial: 32058596
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of MCT (control)
Trial: 35395951
Drug: felzartamab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felzartamab (16 mg/kg per infusion)
Trial: 36463655
Drug: VR-based physical
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-based physical activity program (24 sessions, 40 min each, twice a week)
Trial: 33226501
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment plus daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10, ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02, ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus)
Trial: 33226501
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days)
Trial: 35276963
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (4000 IU daily for 12 weeks)
Trial: 35460163
Drug: App-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based treatment for urinary incontinence
Trial: 33509974
Drug: Oral ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of MSG
Trial: 33509974
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application (swishing) of MSG
Trial: 32366156
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of empagliflozin 5 mg/linagliptin 2.5 mg/metformin XR 1000 mg
Trial: 32366156
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of empagliflozin 25 mg/linagliptin 5 mg/metformin XR 1000 mg
Trial: 32366156
Drug: Free tablet
RxNorm normalized name: Fosfree Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free tablet combinations of empagliflozin/linagliptin/metformin XR
Trial: 34864785
Drug: Sustained WHO
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained WHO risk drinking reductions of 2 or more levels throughout treatment
Trial: 32997744
Drug: Immediate isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate isoniazid preventive therapy (IPT) during pregnancy
Trial: 33820572
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (600 μg RAE/d)
Trial: 33820572
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (10 μg/d)
Trial: 33820572
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vitamin A (600 μg RAE/d) and Vitamin D (10 μg/d)
Trial: 33820572
Drug: Standard anti-tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti-tuberculosis treatment alone (Control group)
Trial: 34233913
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of allogenic cardiosphere-derived cells (CDCs)
Trial: 34371963
Drug: Hydrolyzed chicken
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrolyzed chicken collagen type II (HCII) supplement
Trial: 35753964
Drug: Tailored over-the-counter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored over-the-counter medication safety intervention
Trial: 34945739
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline bolus and midazolam infusion [0.05 mg/kg loading, 20 µg/kg/h thereafter])
Trial: 34945739
Drug: DMED (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMED (saline bolus and dexmedetomidine infusion [1 µg/kg loading, 0.4 µg/kg/h thereafter])
Trial: 34945739
Drug: DEXA (dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEXA (dexamethasone [10 mg] bolus and midazolam infusion)
Trial: 34945739
Drug: DMED‐DEXA (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMED‐DEXA (dexmedetomidine infusion and dexamethasone bolus)
Trial: 34964676
Drug: Electrophysiology-based software-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysiology-based software-guided cochlear implant fitting method (5-electrode method)
Trial: 34964676
Drug: Electrophysiology-based software-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrophysiology-based software-guided cochlear implant fitting method (all 22 electrodes)
Trial: 32517693
Drug: erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erenumab 70 mg and 140 mg
Trial: 39575611
Drug: Morphine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine therapy
Trial: 33252480
Drug: rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg daily (10 mg if co-administered with ritonavir/cobicistat)
Trial: 35461831
Drug: Aflibercept or
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept or bevacizumab treatment
Trial: 33812296
Drug: Family participatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family participatory dignity therapy (2-3 interviews lasting 45-60 minutes each)
Trial: 33812296
Drug: Family participatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family participatory dignity therapy
Trial: 34281600
Drug: Suxiao Jiuxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxiao Jiuxin Pill (SJP)
Trial: 33238677
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (0.5 ml/kg)
Trial: 33238677
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (0.8 ml/kg, flow rate 5 ml/s)
Trial: 33238677
Drug: Flow rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow rates of contrast agents
Trial: 33238677
Drug: Amount of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amount of contrast agent
Trial: 33238677
Drug: Effective dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective dose (ED)
Trial: 34839364
Drug: KET 0.5
RxNorm normalized name: Isoket 0.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KET 0.5 (0.5 mg/kg)
Trial: 34839364
Drug: MID (midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MID (midazolam 0.03 mg/kg)
Trial: 34930986
Drug: Dapagliflozin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin combined with Metformin
Trial: 34657640
Drug: L-arabinose (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arabinose (7.5 g) co-ingested with sucrose (50 g)
Trial: 34657640
Drug: Control (sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sucrose 50 g without L-arabinose)
Trial: 35240074
Drug: Avatrombopag 60
RxNorm normalized name: avatrombopag 60 MG Daily Dose, 20 MG Oral Tablet 15 Count Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag 60 mg once daily for 5 days before and after chemotherapy
Trial: 34186380
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea mouthwash (100 ml for 60 seconds after brushing)
Trial: 34186380
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water mouthwash (100 ml for 60 seconds after brushing)
Trial: 36222372
Drug: Danofloxacin 5
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danofloxacin 5 mg/kg body weight, administered orally (PO)
Trial: 36222372
Drug: Danofloxacin 5
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danofloxacin 5 mg/kg body weight, administered intravenously (IV)
Trial: 32791711
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (waiting treatment)
Trial: 32791711
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (rMS, rTMS, No treatment)
Trial: 34237132
Drug: Anterior quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior quadratus lumborum block with multimodal analgesia (30 ml bupivacaine 0.5% with 2 mg preservative-free dexamethasone)
Trial: 39303788
Drug: High-dose quadrivalent
RxNorm normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose quadrivalent influenza vaccine (QIV-HD)
Trial: 33230964
Drug: Small Changes
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small Changes (daily small changes in intake and activity)
Trial: 33120774
Drug: Triple injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple injection (TI group, n=34)
Trial: 33120774
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (SI group, n=34)
Trial: 36075249
Drug: ABX464 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 100 mg
Trial: 36075249
Drug: ABX464 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 25 mg
Trial: 33405297
Drug: Increasing insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing insulin dose (100% to 160% ICR)
Trial: 35982198
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine bolus of 1.5 mg/kg over 5 min followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively
Trial: 33186492
Drug: Polypill (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (40 mg simvastatin, 100 mg atenolol, 25 mg hydrochlorothiazide, 10 mg ramipril)
Trial: 33186492
Drug: Polypill plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill plus Aspirin
Trial: 33106446
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/kg, 20 min before surgery)
Trial: 33106446
Drug: Psychological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological preparation (booklet and explanation by anaesthesia resident)
Trial: 36424542
Drug: Azithromycin 1000
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000 mg PO once
Trial: 36424542
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg PO once, followed by Azithromycin 250 mg PO daily for four days
Trial: 33693468
Drug: Provitamin A
RxNorm normalized name: Provitamin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provitamin A carotenoid-biofortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Trial: 33693468
Drug: Retinyl palmitate-fortified
RxNorm normalized name: RETINYL PALMITATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate-fortified maize (∼315 µg RE/d to mothers and ∼55 µg RE/d to infants)
Trial: 33693468
Drug: Conventional maize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional maize (0 µg RE/d)
Trial: 34105265
Drug: Aripiprazole orally
RxNorm normalized name: Aripiprazole Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole orally disintegrating tablets (10 mg) in fasting state
Trial: 34105265
Drug: Aripiprazole orally
RxNorm normalized name: Aripiprazole Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole orally disintegrating tablets (10 mg) in fed state
Trial: 34105265
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and reference formulations (both fasting and fed conditions)
Trial: 34105265
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and reference formulations
Trial: 33075170
Drug: Sublingual wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual wafer (25 mg CBD)
Trial: 33075170
Drug: Sublingual wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual wafer (50 mg CBD)
Trial: 33075170
Drug: Oil solution
RxNorm normalized name: Today's Health Mineral Oil Solution
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil solution (50 mg CBD)
Trial: 33075170
Drug: Nabiximols oromucosal
RxNorm normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols oromucosal spray (20 mg CBD, 21.6 mg THC)
Trial: 33075170
Drug: Sublingual wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual wafer (50 mg CBD, multiple doses)
Trial: 33075170
Drug: Sublingual wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual wafer and oil solution
Trial: 33030035
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection (control group)
Trial: 32407460
Drug: Low-dose colchicine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose colchicine (0.5 mg once daily)
Trial: 33884972
Drug: Sevoflurane-propofol combination
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane-propofol combination
Trial: 35660971
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (EXP2–3A)
Trial: 35660971
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (EXP3B–5)
Trial: 38434770
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily
Trial: 33068751
Drug: Active TNS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TNS treatment for 4 weeks
Trial: 33068751
Drug: Sham TNS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham TNS treatment for 4 weeks (control)
Trial: 34903257
Drug: Home-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based intervention combining psychological treatment for depression and a parenting programme (10 sessions: 4 antenatal and 6 postnatal sessions, plus a booster session at 16 months)
Trial: 35433421
Drug: Pembrolizumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab combined with neoadjuvant chemotherapy (neoCT)
Trial: 33142521
Drug: Phytosterols (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols (25 mg/kg)
Trial: 33142521
Drug: Antibiotics (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (200 mg/kg oxytetracycline calcium and 250 mg/kg nosiheptide)
Trial: 35596529
Drug: Intravenous perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous perampanel (12 mg) administered via 30- or 60-minute infusion
Trial: 35596529
Drug: Intravenous perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous perampanel (12 mg)
Trial: 35596529
Drug: Intravenous perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous perampanel
Trial: 33389521
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg dexamethasone phosphate (DEX-P) administered orally (PO)
Trial: 33389521
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg betamethasone phosphate (BET-P) administered orally (PO)
Trial: 33389521
Drug: 1:1 mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 mixture of betamethasone phosphate and acetate (BET-PA) administered intramuscularly (IM)
Trial: 33181081
Drug: Febuxostat (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (80 mg/day, increasing to 120 mg/day if necessary)
Trial: 33181081
Drug: Allopurinol (optimised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (optimised dose)
Trial: 34119741
Drug: JianpiQinghua (JQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JianpiQinghua (JQ) granules (34.8 g) plus omeprazole (10 mg)
Trial: 32133684
Drug: Digital Patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Patient Journey (DPJ) solution
Trial: 33445218
Drug: Endoscopic cyanoacrylate
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic cyanoacrylate injection
Trial: 33032180
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral nutritional supplements (ONS) from the beginning of CCRT
Trial: 34071293
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (10,000 IU daily for 14 days)
Trial: 34980026
Drug: PHI-101 (Chk2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHI-101 (Chk2 inhibitor)
Trial: 34209617
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day of Golden Root Extract (GRE; Rhodiola rosea)
Trial: 35083729
Drug: Probiotic drops
RxNorm normalized name: UpSpring Baby Probiotic Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic drops containing Limosilactobacillus reuteri (DSM 17938 and ATCC PTA 5289) given as 5 daily drops at bedtime for 12 months.
Trial: 34658247
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rivaroxaban plus antiplatelet drug
Trial: 32556409
Drug: Biological graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological graft for EAS repair
Trial: 33981386
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen plus 0.1 mg/kg ondansetron intravenously
Trial: 33981386
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen plus 2 ml of normal saline intravenously
Trial: 32671667
Drug: Baseline GFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline GFR > 60 mL/min/1.73 m2
Trial: 32671667
Drug: Baseline GFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline GFR < 60 mL/min/1.73 m2
Trial: 33158765
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with chemotherapy (≤ 4 cycles of platinum-based chemotherapy with pemetrexed + nivolumab for ≤ 12 cycles as maintenance)
Trial: 33158765
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with chemotherapy
Trial: 33158765
Drug: Chemotherapy (≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (≤ 4 cycles of platinum-based chemotherapy with pemetrexed)
Trial: 32940628
Drug: nab-paclitaxel, 260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel, 260 mg/m2 every 3 weeks
Trial: 32940628
Drug: paclitaxel, 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel, 175 mg/m2 every 3 weeks
Trial: 34903431
Drug: Pelvic radiotherapy
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiotherapy with concurrent chemoradiotherapy followed by adjuvant chemotherapy
Trial: 35276486
Drug: Melatonin 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 36 mg (Mel 36 group; n=6)
Trial: 35276486
Drug: Melatonin 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 18 mg (Mel 18 group; n=6)
Trial: 33246338
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (3-10 mg/L)